Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has announced a 1-for-15 reverse share split effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin on July 29, 2025.
The reverse split will automatically combine every fifteen ordinary shares into one share, with the par value increasing from $0.0009 to $0.0135 per share. The move aims to maintain Nasdaq listing compliance and follows recent preclinical breakthroughs with SIL-204. Shareholders holding shares in book-entry form or through brokers will have their shares automatically adjusted.
Silexion Therapeutics (NASDAQ: SLXN), una società biotecnologica in fase clinica che sviluppa terapie RNAi per i tumori guidati da KRAS, ha annunciato un raggruppamento azionario inverso 1-per-15 che entrerà in vigore dopo la chiusura del mercato il 28 luglio 2025. Le negoziazioni basate sul nuovo numero di azioni inizieranno il 29 luglio 2025.
Il raggruppamento inverso unirà automaticamente ogni quindici azioni ordinarie in una sola azione, con il valore nominale che aumenterà da 0,0009$ a 0,0135$ per azione. Questa operazione mira a mantenere la conformità con i requisiti di quotazione Nasdaq e segue recenti progressi preclinici con SIL-204. Gli azionisti che detengono azioni in forma dematerializzata o tramite broker vedranno le loro azioni adeguate automaticamente.
Silexion Therapeutics (NASDAQ: SLXN), una empresa biotecnológica en etapa clínica que desarrolla terapias RNAi para cánceres impulsados por KRAS, ha anunciado una consolidación inversa de acciones 1 por 15 que entrará en vigor después del cierre del mercado el 28 de julio de 2025. Las operaciones con el ajuste de la consolidación comenzarán el 29 de julio de 2025.
La consolidación inversa combinará automáticamente cada quince acciones ordinarias en una sola, incrementando el valor nominal de $0.0009 a $0.0135 por acción. Esta medida busca mantener el cumplimiento con los requisitos de listado de Nasdaq y sigue a recientes avances preclínicos con SIL-204. Los accionistas que posean acciones en forma electrónica o a través de corredores tendrán sus acciones ajustadas automáticamente.
Silexion Therapeutics (NASDAQ: SLXN)은 KRAS 유전자 변이 암을 위한 RNAi 치료제를 개발하는 임상 단계 바이오텍 기업으로, 2025년 7월 28일 장 마감 후 1대 15 역병합을 시행한다고 발표했습니다. 병합 조정된 거래는 2025년 7월 29일부터 시작됩니다.
역병합은 보통주 15주를 자동으로 1주로 합병하며, 액면가는 주당 0.0009달러에서 0.0135달러로 증가합니다. 이번 조치는 나스닥 상장 요건을 유지하기 위한 것이며, SIL-204의 최근 전임상 성과에 따른 것입니다. 계좌등록 방식 또는 중개인을 통해 주식을 보유한 주주들은 자동으로 주식 수가 조정됩니다.
Silexion Therapeutics (NASDAQ : SLXN), une société biotechnologique en phase clinique développant des thérapies ARN interférents pour les cancers pilotés par KRAS, a annoncé une division inversée d’actions au ratio de 1 pour 15 effective après la clôture du marché le 28 juillet 2025. Les transactions ajustées commenceront le 29 juillet 2025.
Cette division inversée regroupera automatiquement quinze actions ordinaires en une seule, faisant passer la valeur nominale de 0,0009 $ à 0,0135 $ par action. Cette opération vise à maintenir la conformité avec les exigences de cotation du Nasdaq et fait suite à des avancées précliniques récentes avec le SIL-204. Les actionnaires détenant leurs actions sous forme dématérialisée ou via des courtiers verront leurs titres ajustés automatiquement.
Silexion Therapeutics (NASDAQ: SLXN), ein biotechnologisches Unternehmen in der klinischen Phase, das RNAi-Therapien für KRAS-getriebene Krebsarten entwickelt, hat eine 1-zu-15 Reverse-Aktienzusammenlegung angekündigt, die nach Börsenschluss am 28. Juli 2025 wirksam wird. Der Handel auf der angepassten Basis beginnt am 29. Juli 2025.
Die Reverse-Split fasst automatisch jeweils fünfzehn Stammaktien zu einer Aktie zusammen, wobei der Nennwert von 0,0009 US-Dollar auf 0,0135 US-Dollar pro Aktie steigt. Dieser Schritt soll die Einhaltung der Nasdaq-Listing-Anforderungen sicherstellen und folgt auf kürzliche präklinische Durchbrüche mit SIL-204. Aktionäre, die ihre Aktien in Buchform oder über Broker halten, werden automatisch angepasst.
- Recent preclinical breakthroughs achieved with SIL-204 drug candidate
- Strategic move to maintain Nasdaq listing compliance
- Potential to improve ability to conduct future equity financings
- Indicates underlying share price weakness requiring consolidation
- Potential signal of financial distress or market concerns
- May face challenges in maintaining Nasdaq compliance even after split
Insights
Reverse split helps maintain Nasdaq listing but signals depressed share price; potentially enables dilutive financing while pipeline progresses.
Silexion's announced 1-for-15 reverse split represents a significant financial restructuring primarily aimed at regaining Nasdaq compliance. The 15:1 ratio is particularly steep, suggesting the share price has fallen substantially below the
The timing is notable – coming after claimed "preclinical breakthroughs" with their SIL-204 RNAi candidate for KRAS-driven cancers but before entering actual clinical trials. This pattern is common among early-stage biotechs that experience share price erosion during the lengthy development process before reaching value-inflection clinical milestones.
Most concerning is the explicit statement that this move will enable the company to "conduct equity financings" – essentially telegraphing probable share dilution. For current shareholders, this means the reverse split may simply be stage one of a two-part process: first boosting the share price, then issuing new shares at the higher price.
The mechanical implementation appears straightforward with fractional shares being rounded up, and the effective date set for July 29th. This gives shareholders adequate notice, but limited options beyond accepting the adjustment or selling beforehand. The relatively high 15:1 ratio will significantly reduce the outstanding share count, which could potentially increase volatility due to lower liquidity.
Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives
Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol “SLXN.” A new CUSIP number will be assigned to the post-reverse split shares.
As a result of the reverse share split, every fifteen ordinary shares of Silexion issued and outstanding will be automatically combined into one share. The par value of the ordinary shares will be proportionately increased, from
"Our decision to implement this reverse share split reflects Silexion's unwavering commitment to maintaining our Nasdaq listing and strengthening our foundation for future growth," said Ilan Hadar, Chairman and CEO of Silexion. "Following our recent preclinical breakthroughs with SIL-204 and our expanded development strategy across multiple KRAS-driven cancers, I remain highly confident in our ability to advance our innovative RNAi therapeutics toward clinical trials and ultimately deliver meaningful value to both patients and shareholders. This reverse split is designed to enhance our capital markets position, address share price volatility, and support our continued progress toward bringing potentially transformative therapies to patients with difficult-to-treat cancers."
Shareholders holding shares in book-entry form do not need to take any action in respect of the reverse share split, as their shares will be adjusted automatically. Those holding shares through a broker or nominee will also not need to take any action, as the number of shares held by them will be adjusted automatically, as reflected in their brokerage account. For further details, those shareholders should contact their broker.
The reverse share split is intended, among other things, to enable the Company to regain and maintain compliance with Nasdaq’s minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). This adjustment is expected to help Silexion align with Nasdaq standards, enhance its market position, and support its strategic growth initiatives (including by enabling the Company to conduct equity financings).
About Silexion Therapeutics:
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company’s first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, ongoing preclinical studies evaluating SIL204 in colorectal and lung cancer applications, potential expansion of development strategy, and the therapeutic potential of SIL204 across multiple cancer types, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion’s ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com
FAQ
When will Silexion's (SLXN) 1-for-15 reverse stock split take effect?
What is the conversion ratio for Silexion's (SLXN) reverse stock split?
Why is Silexion (SLXN) implementing a reverse stock split?
Do Silexion (SLXN) shareholders need to take any action for the reverse split?
What is Silexion's (SLXN) main business focus?
